Aryl hydrocarbon receptor (AhR)-mediated signaling as a critical regulator of skeletal cell biology
- PMID: 35900841
- PMCID: PMC9448512
- DOI: 10.1530/JME-22-0076
Aryl hydrocarbon receptor (AhR)-mediated signaling as a critical regulator of skeletal cell biology
Abstract
The aryl hydrocarbon receptor (AhR) has been implicated in regulating skeletal progenitor cells and the activity of bone-forming osteoblasts and bone-resorbing osteoclasts, thereby impacting bone mass and the risk of skeletal fractures. The AhR also plays an important role in the immune system within the skeletal niche and in the differentiation of mesenchymal stem cells into other cell lineages including chondrocytes and adipocytes. This transcription factor responds to environmental pollutants which can act as AhR ligands, initiating or interfering with various signaling cascades to mediate downstream effects, and also responds to endogenous ligands including tryptophan metabolites. This review comprehensively describes the reported roles of the AhR in skeletal cell biology, focusing on mesenchymal stem cells, osteoblasts, and osteoclasts, and discusses how AhR exhibits sexually dimorphic effects in bone. The molecular mechanisms mediating AhR's downstream effects are highlighted to emphasize the potential importance of targeting this signaling cascade in skeletal disorders.
Keywords: bone; nuclear receptors; osteoblast; osteoclast; skeletal.
Conflict of interest statement
Declaration of Interest
The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported in this review.
Figures
References
-
- Abney KK and Galipeau J (2021). "Aryl hydrocarbon receptor in mesenchymal stromal cells: new frontiers in AhR biology." FEBS J 288(13): 3962–3972. - PubMed
-
- An L, Shi Q, Fan M, Huang G, Zhu M, Zhang M, Liu Y and Weng Y (2020). "Benzo[a]pyrene injures BMP2-induced osteogenic differentiation of mesenchymal stem cells through AhR reducing BMPRII." Ecotoxicol Environ Saf 203: 110930. - PubMed
-
- Arinze NV, Yin W, Lotfollahzadeh S, Napoleon MA, Richards S, Walker JA, Belghasem M, Ravid JD, Hassan Kamel M, Whelan SA, Lee N, Siracuse JJ, Anderson S, Farber A, Sherr D, Francis J, Hamburg NM, Rahimi N and Chitalia VC (2022). "Tryptophan metabolites suppress the Wnt pathway and promote adverse limb events in chronic kidney disease." J Clin Invest 132(1). - PMC - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
